The comparison with the two previously described HAT1 inhibitors shows that apHAT610 aptamer has affinity for its target in the low nanomolar range similar to that of the bisubstrate inhibitor (28.11 nM for apHAT610 and 1.1 nM for H4K12CoA) [46] and inhibits the growth of the three lung cancer cell lines in the nanomolar range in contrast to the micromolar range for the riboflavin analog JG-2016 [43]. The gene discussed is HAT1; the disease is lung carcinoma.